Hans Wildiers, MD, PhD, of the University Hospitals, Leuven, discusses this phase III study on the use of ado-trastuzumab emtansine vs treatment of physician’s choice in previously treated HER2-positive metastatic breast cancer (Abstract S5-05).
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Sabine Siesling, PhD, of the Netherlands Comprehensive Cancer Organization, discuss the improved...
Mitchell Dowsett, PhD, of the Royal Marsden Hospital discusses the EndoPredict test, which has improved performance compared with the widely used Oncotype Dx test (Abstract S3-01)....
Patricia A. Ganz, MD, of the University of California at Los Angeles, discusses this clinical trial of anastrozole vs tamoxifen in postmenopausal women with ductal carcinoma in sit...
Clifford A. Hudis, MD, of Memorial Sloan Kettering Cancer Center, and William J. Gradishar, MD, of the Lurie Comprehensive Cancer Center, discuss the most importan...
Jame Abraham, MD, of the Cleveland Clinic, discusses findings on the use of avelumab, an anti–PD-L1 antibody, in patients with locally advanced or metastatic breast cancer, as well...
